[{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeterna Zentaris Announces Positive Results In Dose-Finding Pediatric Study Of Macimorelin","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$12.0 million","upfrontCash":"Undisclosed","newsHeadline":"Aeterna Zentaris Announces Pricing of $12 Million Public Offering","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase IV"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"University of Sheffield","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeterna Zentaris Announces Notice of Allowance for U.S. Patent Covering AEZS-150 for the Potential Treatment of Chronic Hypoparathyroidism","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeterna Zentaris Abstract Accepted for Presentation at 13th International Congress on Autoimmunity","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Peptide","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeterna Zentaris Abstract Accepted for Presentation at IMMUNOLOGY2022\u2122, the Annual Event of the American Association of Immunologists","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Peptide","productStatus":"Undisclosed","date":"April 2022","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"AIM Biologicals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Update on Positive Pre-Clinical Results from AIM Biologicals Development Program for the Potential Treatment of Parkinson's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeterna Zentaris Achieves Proof-of-Concept for the Treatment of NMOSD with AIM Biologicals Program","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"IND Enabling"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aeterna Zentaris Set to Regain Full Rights to Macrilen\u2122 (Macimorelin) in U.S. and Canada from Novo Nordisk","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase IV"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aeterna Zentaris Provides Update on Macrilen (Macimorelin), Reiterates Advancement of Pediatric DETECT Trial","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase IV","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase IV"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Ceapro","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Aeterna Zentaris","sponsor":"Ceapro","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Aeterna Zentaris and Ceapro Complete Merger Transaction","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2024","url1":"","url2":"","graph1":"Neurology","graph2":"IND Enabling"}]
Find Clinical Drug Pipeline Developments & Deals by Aeterna Zentaris
The combined company will focus on the development of AEZS-130 (macimorelin), a ghrelin receptor agonist and a small molecule that stimulates the secretion of growth hormone from the pituitary gland.
The combined company will focus on the development of AEZS-130 (macimorelin), a ghrelin receptor agonist and a small molecule that stimulates the secretion of growth hormone from the pituitary gland.
Macimorelin (Macrilen®; GHRYVELIN™), a ghrelin agonist, is an orally active small molecule that stimulates the secretion of growth hormone from the pituitary gland.
Under the Commercial License, Novo Nordisk was granted an exclusive license for the development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the U.S. and Canada.
Preliminary data with mouse 2D2 models of spontaneous autoimmune encephalomyelitis (EAE) indicate that mouse-adapted AIM Biologicals may reduce optic neuritis, loss of inner nuclear layer neurons and EAE symptoms.
Lead Product(s):
Autoimmunity Modifying Biologicals
The pre-clinical data presented showed consistent effects in various in-vitro and in-vivo models, verifying the potential of HLA-G based molecules to induce antigen-specific immune-modulation.
Lead Product(s):
Autoimmunity Modifying Biologicals
AIM Biologicals utilize a novel mechanism based on peptide antigens that are presented on immunosuppressive MHC class I molecules, to selectively and efficiently induce antigen-specific tolerance.
Antigen presentation on MHC class Ib-related molecules induces Aquaporin4-specific regulatory T cells in PBMC from NMOSD patients and prevents experimental autoimmune encephalomyelitis in mice.
AEZS-150 (delayed clearance parathyroid hormone fusion polypeptides DC-PTH), a proprietary fusion protein consisting of a modified GHBP linked to parathyroid hormone PTH1-34 with the goal to provide a PTH analog with delayed clearance of one or two weeks.
Lead Product(s):
Delayed Clearance Parathyroid Hormone
The Company intends to use the net proceeds of this offering for general corporate purposes, which includes funding of a pediatric clinical trial in the E.U. and U.S. for Macrilen, the investigation of further therapeutic uses of macimorelin.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
